Newsroom

Sorted by: Latest
-

ARDT ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Ardent Health, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE:ARDT) securities during the period of July 18, 2024 through November 12, 2025, inclusive (“the Class Period”). If you suffered a loss on your Ardent investments, you have until March 9, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS]...
-

FRMI Investors Have Opportunity to Lead Fermi Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--FRMI Investors Have Opportunity to Lead Fermi Inc. Securities Fraud Lawsuit with the Schall Law Firm...
-

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Skye Bioscience, Inc. (NASDAQ: SKYE) Misled Investors Regarding its Business Ope...
-

FLY Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Firefly Aerospace Inc. (FLY) Investors of Filing Deadline in Class Action Lawsuit

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Firefly Aerospace Inc. (“Firefly”) (NASDAQ: FLY) on behalf of those who purchased or otherwise acquired Firefly: (1) common stock pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with the company’s IPO conducted on or about August 7, 2025; an...
-

Riassunto: Biocytogen e Acepodia ampliano la collaborazione attraverso uno schema di valutazione basato sulle opzioni per ADC bispecifici e con doppio payload (BsAD2C) primi nella categoria

PECHINO, ALAMEDA, Calif. e TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) e Acepodia (6976:TT), oggi hanno annunciato la firma di un accordo di opzione e licenza finalizzato a permettere la valutazione strutturata di programmi coniugati farmaco-anticorpo bispecifico (BsADC) per promuovere ulteriormente lo sviluppo di coniugati farmaco-anticorpo bispecifico con doppio payload (BsAD2Cs). L'accordo accorda ad Acepodia un'opzio...
-

Biocytogen et Acepodia élargissent leur collaboration grâce à un cadre d'évaluation basé sur les options des ADC bispécifiques à double charge utile (BsAD2C) de première génération

BEIJING et ALAMEDA, Californie et TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE : 688796 ; HKEX : 02315) et Acepodia (6976 : TT) ont annoncé aujourd'hui que les entreprises ont conclu un accord d'option et de licence destiné à permettre l'évaluation structurée des programmes de conjugués anticorps-médicament bispécifiques (BsADC) afin de faire progresser le développement de conjugués anticorps-médicament bispécifiques à double charge utile (BsA...
-

Resumen: Biocytogen y Acepodia firman un contrato de opción para fortalecer el desarrollo conjunto de innovadores ADC biespecíficos y de carga dual (BsAD2C)

PEKÍN y ALAMEDA, California, y TAIPÉI, Taiwán--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy la firma de un contrato de opción y licencia con el objetivo de establecer un marco para la evaluación estructurada de programas de conjugados anticuerpo-fármaco biespecíficos (BsADC) y seguir avanzando en el desarrollo de conjugados anticuerpo-fármaco biespecíficos de carga dual (BsAD2C). El acuerdo otorga a Ac...
-

Samenvatting: Biocytogen en Acepodia breiden samenwerking uit door middel van een op opties gebaseerd evaluatiekader voor eersteklas bispecifieke en dual-payload ADC's (BsAD2C)

BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) en Acepodia (6976:TT) hebben vandaag bekendgemaakt dat zij een optie- en licentieovereenkomst hebben gesloten om een gestructureerde evaluatie van bispecifieke antilichaam-geneesmiddelconjugaatprogramma's (BsADC) mogelijk te maken. Hiermee beogen ze de ontwikkeling van bispecifieke antilichaam-geneesmiddelconjugaten met dubbele lading (BsAD2C's) verd...
-

Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C)

PEKING, China, ALAMEDA, Kalifornien, USA, und TAIPEH, Taiwan--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) und Acepodia (6976:TT) haben heute den Abschluss einer Options- und Lizenzvereinbarung bekannt gegeben, die eine strukturierte Evaluierung von Programmen für bispezifische Antikörper-Wirkstoff-Konjugate (BsADC) vorsieht, um die Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten mit doppelter Wirkstoffladung (BsAD2Cs) vor...
-

KBRA Assigns Ratings to MidCap Financial Issuer Trust

NEW YORK--(BUSINESS WIRE)--KBRA assigns an issuer rating of A-, a senior unsecured debt rating of A-, and a junior subordinated debt rating of BBB to MidCap Financial Issuer Trust, a wholly-owed subsidiary of MidCap FinCo Intermediate LLC ("the company" or "MidCap"), which serves as guarantor of the debt. MidCap is a commercial financial company that provides senior secured debt solutions to companies across multiple industries. The company is headquartered in Bethesda, MD. The ratings Outlook...